^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CPGJ-602

    i
    Other names: CPGJ-602, CPGJ602, CPGJ 602, 602
    Company:
    3SBio
    Drug class:
    EGFR antagonist
    Related drugs:
    over2years
    CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study. (ASCO 2022)
    CPGJ602 plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) may have efficacy in KRAS/NRAS/BRAF wild-type metastatic colorectal cancer. CPGJ602 plus mFOLFOX6 could be an option for KRAS/NRAS/BRAF wild-type metastatic colorectal cancer.
    Clinical • P2 data
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • BRAF wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CPGJ-602
    over3years
    Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=75, Recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
    Clinical • Enrollment open • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • CPGJ-602
    over4years
    Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
    Clinical • New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • CPGJ-602